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INVITED REVIEW
Diabetes mellitus is found in as many as 13 mil-
lion people nationally, or 5.2% of the US population,
and more than 650,000 new cases are diagnosed
annually.1 Clinical data that link diabetes to vascular
disease are derived from several large epidemiologic
studies. The Framingham Study of more than 5000
subjects showed that diabetes is a powerful risk fac-
tor for atherosclerotic coronary and peripheral arte-
rial disease, independent of other atherogenic risk
factors, with a relative risk averaging two fold for
men and three fold for women.2 The Framingham
Study results also confirmed that the risk of stroke is
at least 2.5-fold higher in patients with diabetes,3 a
finding that has been confirmed in other large epi-
demiologic studies.4,5 Moreover, diabetes is strong-
ly associated with atherosclerosis of the extracranial
internal carotid artery and thus imparts an addition-
al independent risk of stroke.6
PATHOPHYSIOLOGY OF VASCULAR DIS-
EASE AND COMPLICATIONS OF DIA-
BETES MELLITUS
Overview. Many of the clinical complications of
diabetes may be ascribed to alterations in vascular
structure and function, with subsequent end-organ
damage and death. Specifically, two types of vascular
disease are seen in patients with diabetes: a nonoc-
clusive microcirculatory dysfunction involving the
capillaries and arterioles of the kidneys, retina, and
peripheral nerves, and a macroangiopathy character-
ized by atherosclerotic lesions of the coronary and
peripheral arterial circulation.7-10 The former is rel-
atively unique to diabetes, whereas the latter lesions
are morphologically similar in both patients with and
without diabetes.
Retinopathy is the most characteristic microvascu-
lar complication of diabetes, and population-based
study results have identified a correlation between its
development and the duration of diabetes.11 Similar
correlations have been found with nephropathy, neu-
ropathy, and diabetes,12 with perhaps the strongest
evidence coming from the Diabetes Control and
Complications Trial. The results from the Diabetes
Control and Complications Trial clearly showed a
delay in the development and progression of these
microvascular complications with intensive glycemic
control, thus supporting the direct causal relationship
between hyperglycemia, diabetes, and its microvascu-
lar sequelae.13 These and other clinical trials have pro-
vided the rationale for experimental studies investigat-
ing the fundamental pathophysiology of microvascu-
lar and macrovascular disease in diabetes mellitus.
Microvascular dysfunction in diabetes is mani-
fested by an increased vascular permeability and
impaired autoregulation of blood flow and vascular
tone. These changes culminate into nephropathy,
retinopathy, and neuropathy and most likely con-
tribute to the cardiovascular complications of dia-
betes. Although multiple theories have been postu-
lated as to the cause of accelerated microangiopathy,
it is likely that several biochemical derangements
exist in the presence of hyperglycemia and diabetes
and that these mechanisms work synergistically to
cause microvascular dysfunction. These metabolic
alterations produce functional and structural
changes at multiple areas within the arteriolar and
capillary level, including the basement membrane,9
the smooth muscle cell,14 and, in particular, the
endothelial cell.15
One of the greatest impediments in understanding
vascular disease in patients with diabetes is the miscon-
ception that they have an untreatable occlusive lesion
in the microcirculation.8 This idea originated from a
retrospective histologic study that showed the presence
of periodic-acid-Schiff-positive material occluding the
arterioles in amputated limb specimens from patients
with diabetes.16 However, subsequent prospective
staining and arterial casting studies17,18 and physiolog-
ical studies19 have shown the absence of an arteriolar
occlusive lesion. Dispelling the notion of “small vessel
disease” is fundamental to the principles of limb sal-
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vage in patients with diabetes because arterial recon-
struction is almost always possible in these patients.
Although there is no occlusive lesion in the dia-
betic microcirculation, other structural changes do
exist, most notably, a thickening of the capillary base-
ment membrane. This alteration in extracellular
matrix may represent a response to the metabolic
changes related to diabetes and hyperglycemia.
However, this does not lead to narrowing of the cap-
illary lumen and arteriolar blood flow may be normal
or even increased despite these changes.20 Capillary
basement membrane thickening is the dominant
structural change in both diabetic retinopathy and
neuropathy. In the kidney, nonenzymatic glycosyla-
tion reduces the charge on the basement membrane,
which may account for transudation of albumin, an
expanded mesangium, and albuminuria.21 Similar
increases in vascular permeability occur in the eye and
probably contribute to macular exudate formation
and retinopathy.
In the diabetic foot, basement membrane thick-
ening may theoretically impair the migration of
leukocytes and the hyperemic response after injury
and thus may increase the susceptibility of the dia-
betic foot to infection.22,23 Although resting total
skin microcirculatory flow is similar in both patients
with and without diabetes, the capillary blood flow
is reduced in diabetes, indicating a maldistribution
and functional ischemia of the skin.24 Moreover,
study results of skin microvascular flow have shown
reduced maximal hyperemic response to heat in
patients with diabetes, suggesting that a functional
microvascular impairment is a major contributing
factor for diabetic foot problems. All of these
changes result in an inability to vasodilate and
achieve maximal blood flow after injury.
Diabetes also affects the axon reflex. Injury
directly stimulates nociceptive C fibers, which results
in both orthodromic conduction to the spinal cord
and antidromic conduction to adjacent C fibers and
other axon branches. One function of this axon
reflex is the secretion of several active peptides, such
as substance P and calcitonin gene-related peptide,
which directly and indirectly (through mast cell
release of histamine) cause vasodilation and
increased permeability. This neurogenic vasodilatory
response is impaired in diabetes, further reducing
the hyperemic response when it is most needed: that
is, under conditions of injury and inflammation.25
The previous changes contribute to an early
functional impairment in vascular reserve in the
peripheral, coronary, and cerebral circulation of
patients with diabetes. With positron emission
tomography, myocardial blood flow may be mea-
sured at rest and after vasodilator administration,
and thus coronary flow reserve (as a measure of
endothelial function) may be calculated. Reduced
coronary flow reserve and impaired coronary reac-
tivity has been observed in patients with diabetes
with angiographically normal coronary arteries and
no other detectable microvascular complications,
which suggests an early endothelial dysfunction.26,27
Similarly, cerebrovascular reactivity and reserve
capacity may be assessed with transcranial Doppler
scanning and acetazolamide, which causes vasodi-
latation of the brain resistance vessels. Impaired
cerebrovascular reserve is also noted in patients with
diabetes, particularly among those patients with
other microvascular complications.28
Endothelial function. The normal endotheli-
um plays an important role in blood vessel wall func-
tion and homeostasis by synthesizing and releasing
substances, such as prostacyclin, endothelin, prosta-
glandins, and nitric oxide, which modulate vasomo-
tor tone and prevent thrombosis.29 There is sub-
stantial evidence that endothelial function is abnor-
mal in animal models of diabetes mellitus30-32 and 
in patients with both insulin-dependent and
non–insulin-dependent diabetes mellitus,33,34 thus
directly implicating either hyperglycemia or hyperin-
sulinemia as a possible mediator of abnormal
endothelium-dependent responses. A variety of
mechanisms responsible for vascular dysfunction
have been proposed, principally abnormalities in the
nitric oxide pathway, abnormal production of vaso-
constrictor prostanoids, intracellular signaling,
reduction in Na+,K+–adenosine triphosphatase
(ATPase) activity, and advanced glycosylated end
products.15,27,28,35-37
In 1980, Furchgott and Zawadzki38 discovered
that arterial vasodilation was dependent on an intact
endothelium and its release of a substance they
called endothelium-derived relaxing factor, which
causes arterial smooth muscle relaxation in response
to acetylcholine and other vasodilators.38 Later iden-
tified as endothelial-derived nitric oxide (EDNO), it
activates vascular smooth muscle guanylate cyclase,
elevates cyclic guanosine monophospate levels, and
may increase Na+,K+-ATPase activity.39 A variety of
substances other than acetylcholine may cause
EDNO-mediated vasodilation. Several in vivo stud-
ies with NG-monomethyl-L-arginine (L-NMMA), an
arginine analogue and competitive inhibitor of
EDNO synthesis, have shown that the vasodilatory
effects of insulin are nitric oxide dependent40,41 and
that insulin mediates EDNO-dependent vasodila-
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tion by modulating the synthesis and release of
EDNO. Impaired endothelial-dependent vasodilata-
tion in certain insulin-resistant states may be instru-
mental in the pathogenesis of atherosclerosis and
hypertension and is postulated to be the result of
diminished insulin-mediated EDNO production and
release.42
Studies of patients with insulin-dependent and
non–insulin-dependent diabetes have shown impaired
endothelium-dependent responses to acetylcholine in
both groups but an intact response to exogenous
nitric oxide donors (ie, sodium nitroprusside) in
insulin-dependent diabetes only.33,34 It thus appears
that abnormal nitric oxide release or synthesis pre-
dominates in insulin-dependent diabetes, whereas
non–insulin-dependent diabetes may be characterized
by either a diminished response of smooth muscle to
EDNO or increased inactivation of nitric oxide.
Although there is considerable controversy regard-
ing the role of free radicals in diabetic vascular dis-
ease,43 an increased production of oxygen-derived free
radicals has been described in diabetes and may 
contribute to endothelial dysfunction.44 Superoxide
anions and other oxygen-derived free radicals directly
inactivate endothelium-derived nitric oxide.45 In ani-
mal models, endothelium-derived free radicals impair
EDNO-mediated vasodilatation and administration of
superoxide dismutase and other free radical scavengers
normalize EDNO-dependent relaxation in diabetic
arteries.46 Defective endothelium-dependent relax-
ation in diabetic rat aorta is significantly attenuated by
vitamin E, a potent free radical scavenger.47 In human
studies, administration of vitamin C restores and
improves endothelium-dependent vasodilation, but
not endothelium-independent responses, in patients
with both insulin-dependent and non–insulin-depen-
dent diabetes mellitus, thus further suggesting that
oxygen-derived free radicals may decrease the bioavail-
ability of EDNO.48
A potentially treatable source of oxygen-derived
free radicals is hyperlipidemia. Increased levels of low
density lipoprotein (LDL) and very low density
lipoprotein are common in patients with diabetes.
Hyperglycemia promotes the oxidation and nonen-
zymatic glycation of LDL, which has been strongly
implicated in atherogenesis by a variety of mecha-
nisms.49 In animal models of hypercholesterolemia,
the vascular endothelium produces several free radi-
cals, presumably through xanthine oxidase activation,
and these endothelial-derived free radicals inactivate
EDNO.50 Moreover, flow-mediated vasodilatation
and reactive hyperemia (endothelium-dependent) are
more impaired in patients with insulin-dependent
diabetes and elevated LDL cholesterol levels, which
further supports the relationship of hypercholes-
terolemia, free radicals, and EDNO.51
Advanced glycosylation end products (AGEs) have
also been implicated in the pathogenesis of diabetic
microvascular complications.37 These are formed from
a reversible reaction between glucose and protein to
form Schiff bases, which then rearrange to form stable
Amadori-type early glycosylation products. Some of
these reversible early glycosylation products may
undergo complex rearrangements to form irreversible
AGEs. In experimental diabetes, AGEs impair the
actions of EDNO and cause an impaired endothelium-
dependent response, which is ameliorated by the
administration of an AGE inhibitor.52 AGEs also dis-
place disulfide crosslinkages in collagen and scleral pro-
teins, accounting for the diminished charge in the cap-
illary basement membrane. This may contribute to the
increased vascular permeability of diabetes because
blockade of a specific receptor for AGE reverses dia-
betes-mediated vascular hyperpermeability.53 More-
over, the presence of AGE receptors on both endothe-
lial cells and monocytes, along with AGE deposition in
the subendothelium, suggests monocyte deposition
into the subendothelial space and secondary complica-
tions.54 Makita et al,55 with a radioreceptor assay for
AGEs in serum and arterial wall, have demonstrated
higher AGE levels in patients with diabetes as com-
pared with nondiabetic control subjects, with the
highest levels occurring among patients with diabetes
with nephropathy.55 Because at least part of AGE-
induced cellular dysfunction is the result of an oxidant-
sensitive mechanism, which is inhibited by antioxi-
dants, it is likely that both oxygen-derived free radicals
and AGEs each contribute to cause impaired EDNO-
dependent vasodilation in diabetes. Taken together,
the effects of AGEs on vascular permeability, suben-
dothelial protein deposition, inactivation of nitric
oxide, and modification of LDL provide strong evi-
dence of their important role in diabetic vascular 
disease.
Experimental studies in diabetic animals have
also indicated that abnormal endothelial production
of vasoconstrictor prostanoids, notably thrombox-
ane A2 and prostaglandin H2, may be a cause of
endothelial cell dysfunction. Increased levels of
thromboxane A2 have been isolated only from seg-
ments of diabetic aortic tissue with intact endotheli-
ums, which suggests that the endothelium is respon-
sible for the increased release, and impaired relax-
ation to acetylcholine in these segments is restored
by treatment with cyclooxygenase inhibitors.15,35 In
humans, however, the role of vasoconstrictor
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prostanoids is less clear. Flow-dependent vasodila-
tion in healthy subjects, which may be used as an
index of endothelial function, is abolished by L-
NMMA but unaffected by aspirin, thus showing that
it is entirely mediated by EDNO and independent of
vasoactive prostanoids.56 Moreover, the attenuated
endothelium-dependent vasodilation after acetyl-
choline administration seen in patients with diabetes
is not affected by pretreatment with cyclooxygenase
inhibitors.33,34
The microcirculation and neuropathy. Several
lines of evidence have indicated that microcircula-
tion is also implicated in the pathogenesis of diabet-
ic neuropathy, and in fact, the cause of diabetic neu-
ropathy is a complex interplay between metabolic
and microvascular defects. Hyperglycemia induces
an increase in the polyol pathway by which glucose
is metabolized to sorbitol via aldose reductase.
Increased aldose reductase activity impairs myo-
inositol uptake, which leads to decreased Na+,K+
ATPase activity and loss of electrical conduction in
neural tissue.57,58
There is also a relationship between aldose
reductase, Na+,K+-ATPase activity, and nitric oxide
in the pathogenesis of diabetic neuropathy. First,
Na+,K+-ATPase activity in normal arteries is depen-
dent on an intact endothelium, which suggests a
stimulatory action by EDNO.59 Second, hyper-
glycemia causes decreased Na+,K+-ATPase activity in
normal rabbit aorta, an effect that is preventable
with the administration of aldose reductase inhib-
itors or with the raising of plasma myo-inositol lev-
els.30 Third, the administration of L-NMMA, an
EDNO inhibitor, decreases Na+,K+-ATPase activity
in the aortic wall.24 In addition, L-NMMA adminis-
tration reverses the protective effects of aldose
reductase inhibitor treatment on nerve conduction
velocity.60 It therefore seems likely that microvascu-
lar endothelial dysfunction plays a significant role in
the pathogenesis of diabetic neuropathy and that at
least part of this is caused by the metabolic derange-
ments of diabetes.
Recent studies from our laboratory have helped
further define the relationship between microcircula-
tion, diabetes, and neuropathy.61,62 With laser Dop-
pler scan imaging to measure the vasodilatory re-
sponse to acetylcholine (endothelium-dependent)
and sodium nitroprusside (an exogenous nitric oxide
donor, endothelium-independent), we have found
that the endothelium-dependent vasodilatation and
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Fig 1. Depiction of role of endothelial nitric oxide (NO) and nitric oxide synthetase (NOS)
in vasodilatory response to acetylcholine (endothelium-dependent response). In contrast, sodi-
um nitroprusside, as exogenous nitric oxide donor, directly activates cyclic guanosine
monophospate (cGMP) with resultant vasorelaxation. TXA2, Thromboxane A2; PGs,
prostaglandins.
the axon reflex are impaired in the presence of dia-
betes and neuropathy but the endothelium-indepen-
dent response is spared (Fig 1). This dysfunction may
be attributed to an impaired production of nitric
oxide. This is also correlated anatomically (with
immunostaining techniques), in that expression of
endogenous endothelial nitric oxide synthetase is
reduced in patients with diabetic neuropathy.62
Other causes for diabetic neuropathy include a
localized nerve “hypoxia,” as the result of reduced
endoneurial blood flow, increased vascular resis-
tance,63,64 and decreased endothelial production of
nitric oxide.60 Although microvascular dysfunction
has been mainly implicated, the role of peripheral
vascular disease remains considerable because it
appears likely that a decrease in total limb blood flow
would potentiate nerve ischemia.65,66 Studies from
the authors’ clinical laboratory have shown that
reversal of hypoxia (by arterial reconstruction) halts
the progression of neuropathy, lending further sup-
port to the role of hypoxia in the pathogenesis of
nerve dysfunction in diabetes mellitus.67,68
DIABETES AND CEREBROVASCULAR 
DISEASE
Compelling data from several large clinical stud-
ies have shown that diabetes is a major risk factor for
stroke and that the incidence of ischemic stroke is at
least 2.5-fold higher in patients with diabetes.3-5
Moreover, the mortality and severity of stroke is
higher among patients with diabetes.69,70 The rela-
tive risk of stroke increases even further among
patients with diabetes with established retinopathy,
neuropathy, or nephropathy, thus suggesting that
the presence of diabetes introduces additional
microvascular and cerebrovascular pathophysiology,
which may increase the frequency and severity of
stroke in these patients.71,72
Elevated blood glucose levels are toxic to infarct-
ed brain tissue, and stroke severity is greater in
patients with hyperglycemia.73,74 Among patients
with diabetes, poor glycemic control doubles the risk
of ischemic stroke, even after adjustment for other
variables.75 Abnormal cerebral blood flow may be
seen in experimental diabetes, and among patients
with diabetes and no history of cerebrovascular dis-
ease, single photon emission tomography scanning
has shown multiple subclinical alterations in cerebral
blood flow.76 Hyperglycemia alone causes both a
decrease in cerebral blood flow and an impaired cere-
bral vasodilatory response.77 As noted previously,
altered cerebral vascular reactivity occurs among
patients with long-standing diabetes and may reflect a
generalized cerebrovascular microangiopathy involv-
ing the brain resistance arterioles.28
Acute hyperglycemia and glucose exposure may
also impair the autoregulation of cerebral blood flow.
In vitro exposure of isolated cerebral arteries to high
glucose concentrations causes vasodilation and inhi-
bition of arterial tone, suggesting that both cere-
brovascular tone and control of cerebral blood flow
may be impaired during acute hyperglycemia.78
Moreover, because removal of the endothelium abol-
ishes this effect, this appears to be an endothelial-
dependent and nitric oxide–mediated mechanism.
Multiple cerebrovascular metabolic abnormalities
also contribute to the worse stroke outcome in
hyperglycemia and diabetes.79 Anaerobic metabolism
of glucose during ischemia produces lactate, which
accumulates inside brain cells and results in lower
intracellular pH and cell death. As noted earlier,
AGEs accumulate as a consequence of diabetes and
may also contribute to the increased stroke severity in
patients with diabetes because systemic administra-
tion of AGEs into animals with focal brain infarction
increases the cerebral infarct size and damage.80
Because of the worse prognosis of stroke in
patients with diabetes, efforts should be directed
toward the reduction of the risk of stroke in these
patients, including reduction or elimination of con-
comitant risk factors. In addition, among selected
symptomatic and asymptomatic patients with a high-
grade internal carotid artery stenosis, carotid
endarterectomy has been shown to reduce the risk of
stroke.81,82 Because diabetes is associated with multi-
ple cerebrovascular abnormalities, the safety of
carotid endarterectomy in patients with diabetes may
be questioned.83 A recent report from the authors’
institution summarized the experience with carotid
endarterectomy in patients with diabetes.84 During a
6-year period, 732 carotid endarterectomy proce-
dures were performed, 284 (39%) of which were in
patients with diabetes mellitus. The total operative
mortality rate was 0.3%. There were 11 perioperative
neurologic events (1.5%; eight strokes, and three tran-
sient ischemic attacks) during the entire period, six
(2.1%) of which were among patients with diabetes
and five (1.1%) of which were among patients without
diabetes, a difference that was not statistically signifi-
cant. Of the eight strokes, three (1.0%) occurred in
patients with diabetes and five (1.1%) in patients with-
out diabetes, which again was not statistically signifi-
cant. Moreover, it was shown that diabetes is not an
independent risk factor for postoperative cardiac 
morbidity among patients who undergo carotid
endarterectomy. These results showed that carotid
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endarterectomy may be safely performed in patients
with diabetes, with neurologic morbidity and mor-
tality rates that are comparable with those of the non-
diabetic population.
THE DIABETIC FOOT
Problems of the diabetic foot are the most com-
mon cause for hospitalization in patients with dia-
betes, with an annual health care cost of more than
$1 billion.85 Diabetes is a contributing factor in half
of all lower extremity amputations in the United
States, and the relative risk for amputation is 40
times greater in people with diabetes.86 Diabetic
foot ulceration will affect 15% of all individuals with
diabetes during their lifetime and is clearly a signifi-
cant risk factor in the pathway to limb loss.87 The
principal pathogenetic mechanisms in diabetic foot
disease are neuropathy, infection, microvascular dys-
function, and ischemia; acting together, they con-
tribute to the sequence of tissue necrosis, ulceration,
and gangrene (Fig 2).
As discussed previously, the cause of diabetic
neuropathy is unknown and most likely multifactor-
ial. Peripheral neuropathy is a common complication
of diabetes, afflicting as many as 50% to 60% of all
patients88,89 and is present in more than 80% of
patients with diabetes with foot lesions, thus further
emphasizing the direct relationship between neu-
ropathy and foot ulceration.90 Broadly classified as
focal and diffuse neuropathies, the latter is more
common and includes the autonomic and chronic
sensorimotor polyneuropathies, which both con-
tribute to foot ulceration.
The spectrum of infection in diabetic foot disease
ranges from superficial ulceration to extensive gan-
grene with fulminant sepsis. Classical signs of infec-
tion may not always be present in the infected dia-
betic foot because of the consequences of neuropa-
thy, alterations in the foot microcirculation, and
leukocyte abnormalities. Fever, chills, and leukocy-
tosis may be absent in up to two thirds of patients
with diabetes with extensive foot infections, and
hyperglycemia is often the sole presenting sign.91
Therefore, a complete examination of the infected
areas is mandatory and the wound should be thor-
oughly inspected, including unroofing of all encrust-
ed areas, to determine the extent of involvement.
Most infections are polymicrobic, the most com-
mon pathogens being staphylococci, streptococci, and
enterococci; anaerobes and gram-negative bacilli are
also commonly cultured.92 Cultures should be
obtained from the base of an ulcer or abscess cavity
after debridement. Osteomyelitis is common in dia-
betic foot ulceration, appearing in almost 70% of
benign-appearing ulcers93 and should be presumed if
the bone is palpated on probing in an open ulcer.94
Ischemia is a fundamental consideration to the
vascular surgeon faced with the diabetic foot.95
The combination of motor and sensory neuropathy
along with loss of the neurogenic inflammatory
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Fig 2. Underlying mechanisms of diabetic foot ulceration. Sensorimotor neuropathy leads to
diminished sensation and small muscle atrophy in foot, resulting in flexed metatarsals,
metatarsal head prominence, and clawing of toes. Altered architecture of foot, coupled with
ischemia and microvascular dysfunction, ultimately leads to ulceration.
response and microcirculatory dysfunction results
in a biologically compromised foot. Even moderate
ischemia may lead to ulceration under these cir-
cumstances, and thus the concept of ischemia must
be modified in making decisions about arterial
reconstruction. The biologically compromised foot
necessitates maximum circulation to heal an ulcer.
This leads to three significant principals: (1) all dia-
betic foot ulcers should be evaluated for an
ischemic component; (2) correction of a moderate
degree of ischemia will improve healing in the bio-
logically compromised diabetic foot; and (3) when-
ever possible, the arterial reconstruction should be
designed to restore normal arterial pressure to the
target area.
Treatment of the diabetic foot should be direct-
ed towards the pathogenic factors outlined previous-
ly. In general, this can be broken down into a few
simple guidelines:96
1. Prompt control of infection. This assumes first
priority in the management of any diabetic foot
problem.
2. Evaluation for ischemia.
3. Prompt arterial reconstruction once active infec-
tion has resolved.
4. Secondary procedures, such as further debride-
ment, toe amputations, local flaps, and even free
flaps, may then be carried out separately in the
fully vascularized foot.
DIABETES AND LOWER EXTREMITY VAS-
CULAR DISEASE
Unlike microvascular disease, which is unique to
diabetes and its metabolic alterations, the cause of
lower extremity ischemia is similar in both patients
with and without diabetes and is the result of accel-
erated atherosclerosis. One notable difference
between these populations is the pattern and loca-
tion of the occlusive atherosclerotic lesion. As noted
earlier, there is no evidence for an occlusive lesion at
the arteriolar level (“small-vessel disease”) in
patients with diabetes. However, patients with dia-
betes are more likely to have atherosclerotic disease
affecting the infrageniculate arteries, with sparing of
the foot arteries,97 which allows for successful arter-
ial reconstruction to these distal vessels.
Because the foot vessels are often patent in the
patient with diabetes and because of the success of
bypass grafting to these vessels, an appropriate eval-
uation for ischemia is essential in patients with dia-
betes. Unless recognized and corrected, limb salvage
efforts will fail even if infection and neuropathy have
been appropriately treated. The most important
observation is the presence or absence of a palpable
foot pulse; in simplest terms, if the foot pulses are
not palpable, it can be assumed that occlusive disease
is present.
A variety of noninvasive arterial tests may be
ordered. However, in the presence of diabetes, all of
these tests have significant limitations. Medial arter-
ial calcinosis occurs frequently and unpredictably in
patients with diabetes, and its presence can result in
noncompressible arteries with artifactually high seg-
mental systolic pressures and ankle-brachial indices.
Lower levels of calcification in the toe vessels sup-
port the use of toe systolic pressures,98 but their use
is often limited by the proximity of the foot ulcer to
the cuff site. Segmental Doppler wave forms and
pulsed volume recordings are unaffected by medial
calcification, but evaluation of these waveforms is
primarily qualitative and not quantitative. In addi-
tion, the quality of the waveforms is affected by
peripheral edema, and the presence of ulceration
precludes accurate cuff placement. Regional transcu-
taneous oximetry measurements are also unaffected
by medial calcinosis, and recent studies have noted
its reliability in predicting healing of ulcers and
amputation levels.99 Limitations, including a lack of
equipment standardization, user variability, and a
large “gray area” of values, preclude its applicability.
Furthermore, transcutaneous oximetry measure-
ments are higher in patients with diabetes with foot
ulcers when compared with the nondiabetic popula-
tion, which further limits the ability of this test to
predict ischemia.100 Therefore, although they have
been used to predict healing in patients without dia-
betes, a high value may not correlate with healing
potential in the presence of diabetes.
PRINCIPLES OF ARTERIAL RECON-
STRUCTION IN THE DIABETIC FOOT
The limitations of noninvasive vascular testing
in patients with diabetes with foot ulceration
emphasize the continued importance of a thorough
bedside evaluation and clinical judgment. The sta-
tus of the foot pulse is the most important aspect
of the physical examination. An absent foot pulse is
an indication for contrast arteriography in the clin-
ical setting of tissue loss, poor healing, or gan-
grene, even if neuropathy may have been the
antecedent cause of skin breakdown or ulceration.
Importantly, because the foot vessels are often
spared by the atherosclerotic occlusive process,
even when the tibial arteries are occluded, it is
essential that arteriograms not be terminated at the
midtibial level. The complete infrapopliteal circula-
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 2 Akbari and LoGerfo 379
tion should be incorporated, including the foot
vessels. The advent of digital subtraction angiogra-
phy has greatly helped in the visualization of these
distal vessels. Both anteroposterior and lateral foot
views should be included. Excessive plantar flexion
should be avoided because this may impede flow in
the dorsalis pedis artery.
A complete arteriogram will facilitate choosing
an outflow artery that will restore a palpable foot
pulse. Proximal bypass grafting to the popliteal or
tibioperoneal arteries may restore foot pulses. More
often, however, because of the pattern of occlusive
disease in the patient with diabetes, bypass grafting
to the popliteal or even tibial arteries cannot accom-
plish this goal because of more distal obstruction.
Similarly, although excellent results have been
reported with peroneal artery bypass grafting,101 the
peroneal artery is not in continuity with the foot ves-
sels and may not achieve maximal flow, particularly
to the forefoot, to achieve healing.
Restoration of the foot pulse is a fundamental
goal of revascularization in the diabetic foot.
Autogenous vein grafting to the dorsalis pedis artery
represents a technical advance that provides durable
and effective limb salvage.102 Fundamental to the
success of the dorsalis pedis bypass graft is meticu-
lous technique and its appropriate use. The principal
indication for the pedal graft is when there is no
other vessel that has continuity with the foot, partic-
ularly in cases with tissue loss. Although the dorsalis
pedis bypass graft may be effectively used for salvage
of ischemic heel ulceration,103 preference should be
given to the posterior tibial artery if it is in continu-
ity with the foot. Dorsalis pedis bypass grafting is
unnecessary when a more proximal bypass graft will
restore foot pulses and should not be done if there
is an inadequate length of autogenous vein. In addi-
tion, if the dorsum of the foot is extensively infected
and the peroneal artery is of good quality on the
preoperative arteriogram, preference should be
given to peroneal artery bypass grafting.
The distal location of the dorsalis pedis artery
theoretically necessitates a long venous conduit,
which is often not attainable. However, with the use
of the popliteal or distal superficial femoral artery as
an inflow site, a shorter length of vein may be used,
with excellent long-term patency.104 This is particu-
larly true in the patient with diabetes, again because
of the pattern of atherosclerotic disease. The vein
graft to the dorsalis pedis artery can be prepared as
an in situ, reversed, or non-reversed vein graft, with-
out any significant difference in outcome.105
Concomitant angioscopic assessment of the harvest-
ed vein should be performed to detect any intralu-
minal abnormalities.106 In the absence of saphenous
vein, autogenous arm vein grafts may be used and
provide comparable limb salvage rates.107 The
authors have had no experience with prosthetic
bypass grafting to the dorsalis pedis artery and do
not recommend its use.
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Fig 3. Since 1984, there has been a significant drop in major amputations at the authors’ insti-
tution, concomitant with a rise in distal lower extremity arterial reconstruction. (With permis-
sion from LoGerfo FW, Gibbons GW, Pomposelli FB Jr, et al. Trends in the care of the dia-
betic foot: expanded role of arterial reconstruction. Arch Surg 1992;127:617-21.).
Because of the presence of medial arterial calcifi-
cation in patients with diabetes, severe calcification
of the outflow artery may be encountered, but this
should not preclude attempts at arterial reconstruc-
tion.108 Moreover, active infection in the foot is not
a contraindication to dorsalis pedis bypass grafting,
as long as the infectious process is controlled and
away from the proposed incision area.109
We have recently reported our experience with
dorsalis pedis arterial bypass grafting in 367 patients
during an 8-year period, with a perioperative mor-
tality rate of 1.8%.110 Tissue loss was an indication
for surgery in almost 85% of the patients. Twenty-
nine grafts (7.5%) failed within the first 30 days, but
19 were successfully revised when a correctable tech-
nical problem was found at reoperation. The actuar-
ial primary and secondary patency and limb salvage
rates were 68%, 82%, and 87%, respectively, at 5
years of follow-up.
After successful revascularization, secondary pro-
cedures may be performed for both limb and foot
salvage. Chronic ulcerations may be treated with
ulcer excision, arthroplasty, or hemiphalangectomy.
In the patient with extensive tissue loss, both local
flaps and free flaps may be used. Because of the
architecture of the diabetic foot, underlying bony
structural abnormalities are often the cause of ulcer-
ation and may be corrected with metatarsal head
resection or osteotomy. Heel ulcers may be treated
with partial calcanectomy and local (eg, flexor ten-
don) or even free flap coverage.
SUMMARY
This aggressive and systematic approach to dia-
betic foot disease has resulted in improved limb sal-
vage among patients with diabetes. At the authors’
institution, there has been a significant reduction in
every category of lower limb amputation since 1984
(Fig 3).111 Concomitant with this decrease has been
an increase in the number of patients who undergo
arterial reconstruction and a greater application of
the dorsalis pedis bypass graft. An awareness and
understanding of the complex pathophysiology of
diabetic microvascular and macrovascular disease
will lead to further decreases in lower limb amputa-
tion and reduce the overall morbidity and mortality
of diabetes in general.
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